|
業務類別
|
Biotechnology |
|
業務概覽
|
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer. |
| 公司地址
| 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801 |
| 電話號碼
| +1 781 222-9600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.replimune.com |
| 員工數量
| 465 |
| Ms. Emily Hill |
Chief Financial Officer |
美元 266.54K |
29/06/2026 |
| Dr. Sushil Patel, PhD |
Director and Chief Executive Officer |
-- |
29/06/2026 |
| Dr. Konstantinos Xynos, M.D. |
Chief Medical Officer |
美元 499.20K |
19/07/2024 |
| Mr. Andrew Schwendenman |
Chief Accounting Officer |
-- |
29/06/2026 |
| Mr. Christopher Sarchi |
Chief Commercial Officer |
-- |
19/07/2024 |
| Mr. Paul Bullock |
Chief Manufacturing Officer |
-- |
26/03/2024 |
|
|
| Mr. Joseph P. Slattery, C.P.A. |
Independent Director |
29/06/2026 |
| Mr. Paolo Pucci |
Independent Director |
29/06/2026 |
| Dr. Kapil Dhingra, M.B.B.S. |
Independent Director |
29/06/2026 |
| Mr. Philip Astley-Sparke |
Executive Chairman of the Board |
29/06/2026 |
| Mr. Dieter Weinand |
Lead Independent Director |
29/06/2026 |
| Mr. Madhavan Balachandran |
Independent Director |
29/06/2026 |
| Ms. Christy J. Oliger |
Independent Director |
29/06/2026 |
| Dr. Sushil Patel, PhD |
Director and Chief Executive Officer |
29/06/2026 |
| Ms. Veleka Peeples-Dyer |
Independent Director |
29/06/2026 |
| Mr. Michael Goller |
Independent Director |
29/06/2026 |
|
|
|
|
